South Korea's drug safety ministry has given official approval to the antibody COVID-19 treatment developed by the local pharmaceutical company Celltrion.
The treatment is called Rekirona.
It's the country's first locally made antibody treament, and it's for severely-ill COVID-19 patients aged over 50.
Celltrion submitted the results of the global phase of the third clinical trial last month.
It now plans to accelerate its efforts to get full authorization in other countries.